Loading...
Teprotumumab: a disease modifying treatment for graves’ orbitopathy
BACKGROUND: On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. DISCUSSION: This article discu...
Na minha lista:
| Udgivet i: | Thyroid Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7334856/ https://ncbi.nlm.nih.gov/pubmed/32636936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13044-020-00086-7 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|